Connect with us

Stock Picks

Stock Pick: Novavax can be a Big Winner in 2017

Published

on

Novavax (NASDAQ:NVAX) develops vaccines based on protein nanoparticles which can help increase the immune response in patients. It is currently awaiting results of phase 3 trial. A successful result will provide significant bump to the stock and also make it an attractive acquisition target by bigger pharmaceutical companies.

RSV F maternal vaccine candidate in phase 3

Data from RSV F vaccine in phase 3 will show its efficacy. We should see the results by the second half of this year. If the results are excellent it will allow Novavax to target 4 million people.

[ecko_annotated header=”Novavax’s RSV F vaccine is the only candidate in phase 3″ annotation=””]

[/ecko_annotated]

The market opportunity of this vaccine is enormous. Close to 57,000 children younger than 5 years are hospitalized due to RSV infection. Being the only drug can provide significant advantage to Novavax. The RSV F vaccine for maternal immunization is estimated to have annual US cost burden of around $770 million. For older adults this burden is a staggering $28 billion. NVAX will be able to launch the RSV F vaccine for maternal immunization by early 2018 whereas vaccine for older adults can be launched in 2019.

[ecko_annotated header=”Big market opportunity for Novavax vaccines” annotation=””]

[/ecko_annotated]

Peak sales target

The past success rate of phase 3 drugs getting FDA approval is close to 50%. According to NVAX the market opportunity for maternal immunization vaccine is close to $770 million. This would result in a peak sales estimate of $380 million as there is no other competition for this drug. Valuation of a clinical stage biotech company is between 3-5 times its peak sales. Taking a conservative estimate, this $380 million in peak sales will translate to a $1.14 billion market capitalization for the company. Currently the stock has a market cap of $223 million.

[ecko_annotated header=”Probability of success for a drug at different stages” annotation=””]

[/ecko_annotated]

Currently the stock is trading at $0.82/share. If the above approval is provided we can see the stock skyrocket to $4-$4.5/share. Becoming an acquisition target soon after approval will also provide a good premium valuation to the stock in a short time.

Risk/Reward associated with the stock

Although the upside for the stock is quite strong at the present moment, it should be noted that everything hinges on RSV F vaccine getting FDA approval. In case this vaccine does not meet the requisite standards we should see a slump in the shares. A similar event happened in September 2016 when RSV F vaccine did not meet the standards for older patients. This led to over 80% fall in its stock price.

[ecko_annotated header=”Fall in NVAX prices after its last drug failure in meeting the standards on older patients in September 2016″ annotation=””]

[/ecko_annotated]

Investor Takeaway

Novavax is developing RSV F vaccine for Respiratory Syncytial Virus. This vaccine for infants through maternal immunization is in Phase 3 and the results should be declared in the latter half of 2017. If it gets the requisite approval from FDA, it will be the first drug in the market for RSV segment and will have a peak sales market opportunity of $380 million. This can boost the price of the stock to over $4/share from current price of $0.80/share.

If it goes through the acquisition route, the stock valuation can increase much sooner. However, traders much also be aware of the risk associated with this stock. The stock is heavily reliant on the positive outcome of its RSV F vaccine and if this does not happen, we can see a decline in the stock for quite some time.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...





Feedback or Requests?

2 Comments

2 Comments

  1. Ershad

    April 22, 2017 at 10:27 pm

    Hi Rohit,

    Thanks for your article I wanted to ask a questions firstly how does one buy shares into this company? Secondly what are the probality that this new drug gets an approval from the FDA?

    Kind regards
    Ershad

    • Pabloasampras

      May 1, 2017 at 3:04 am

      Hi bud , you can open an independent investing account with Merryl Lynch

You must be logged in to post a comment Login

Leave a Reply

Activism

Stock Pick: Philip Morris

Published

on

Philip Morris International Incorporated is an American multinational firm that manufactures cigarettes and tobacco. Its products including its best-seller Marlboro cigarettes that are sold in over 180 countries around the world. The company has a diverse workforce of over 81,000 employees and touts an estimated 150 million consumers worldwide. In 2017, Philip Morris generated 7.8 billion dollars in revenues.

Technical Analysis of Philip Morris (PM)

PM looked toppish in June 2017 when it failed to take out resistance of $120 after two attempts. On top of that, the stock was trading in extreme overbought territory on the weekly chart. These were indications that bulls were exhausted.

Things went from bad to worse when the stock breached support of $110. This activated the head and shoulders reversal pattern on the daily chart and effectively reversed the trend. The downtrend saw PM drop to as low as $76.21 in June 2018. However, it appears that the worst may be over for the stock.

Technical analysis show that PM is respecting key support of $78. Bulls have defended this level since February 2012. It looks like they will continue to take control of this price level, especially after PM successfully backtested the support in August 2018.

In addition, we can see the weekly RSI breakout from its own falling wedge pattern. This is an indication that bulls are significantly gaining momentum.

Fundamental Analysis of Philip Morris (PM)

In addition, we have fundamental analysis to back up our bullish view. PM’s trailing twelve month price to earnings ratio stands at 19.78. The stock is still relatively undervalued considering that it has a five-year maximum of 28.51. This suggests that investors are generally willing to pay more for PM stocks.

On top of that, Zacks reports that Philip Morris beat expert projections for the second quarter of 2018. Analysts estimated that PM would generate revenues of $7.528 million and an earnings per share (EPS) of $1.23. However, PM brought in revenues of $7.726 million and an EPS of $1.41. With these developments, even the Wall Street Journal is overweight on the stock as they published a target price of $93.27.

The strategy is to buy as close to $78 support as possible. If bulls can successfully defend the support, then PM might be able to rally to our target of $95.

The timeline for the target is less than six months.

Weekly PM Chart

Monthly PM Chart

As of this writing, the Philip Morris International Incorporated stock (PM) is trading at 81.93.

Summary of Strategy

Buy: As close to 78 support as possible.

Target: 95

Stop: Close below 76.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

3.6 stars on average, based on 235 rated postsKiril is a financial professional with 4+ years of experience in financial writing, analysis and product ownership. He has passed all three CFA exams on first attempt and has a bachelor's degree with a specialty in finance. Kiril’s current focus is on cryptocurrencies and ETFs, as he does his own crypto research and is the subject matter expert at ETFdb.com. He also has his personal website, InvestorAcademy.org where he teaches people about the basics of investing. His ultimate goal is to help people with limited knowledge of finance and investments to create investment portfolios easily, and in line with their unique circumstances.




Feedback or Requests?

Continue Reading

Analysis

NIO Means Tesla Monopoly Ends

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

On Sep 12, NIO made its IPO on the NYSE, which is a very important event for all automotive investors. Founded in 2014 by William Lee, NIO is one of the first companies to compete with Tesla in the premium electric car segment. NIO is based in Shanghai, China, and it already got investment support from such renowned companies as Baidu, Lenovo, Temasek, Tencent, Sequoia, and others.

There are currently over 4,000 employees at NIO.

In June 2018, the company started selling NIO ES8; currently, 481 electric cars have been sold and 17,000 more have been pre-ordered. This is Tesla Model X’s direct competition, while its price is twice as low thanks to some good support from the Chinese government, which is interested in promoting electric cars.

NIO ES8 starts from $67,000 (basic configuration). It has two engines of 635 horsepowers and can ride 355 km before charging. A good difference from Tesla is an option to use replaceable batteries; the monthly subscription is $193, and it takes just around 3 minutes to replace a battery. Tesla planned to offer this option, too, but did not implement it.

The underwriters of NIO at NYSE were BofA Merrill Lynch, Citi, Credit Suisse, Deutsche Bank, Goldman Sachs, JPMorgan, Morgan Stanley, and UBS. The initial price per share was $6.26. During the first day, 160M of shares were sold, which allowed NIO to get around $1B and get a place in top US IPO’s rating in 2018.

During the first day, the share price increased to $7, while the next day it jumped above $13, allowing investors to make over 100% profit. This shows investors are very much interested in the company, perhaps because of the good pre-IPO promotion. Before buying NIO shares now, though, one should wait first for the volatility to calm down.

Comparing Tesla and NIO is not the best job now, as Tesla already has over 14-year experience; however, this comparison may well become valid in a year or two, when more data arrive. While NIO is just starting out, its management may make accidental mistakes.

The lockup period (the period during which investors are not allowed to sell their shares) is 180d, which may additionally support the price, while after that the Q2 results will come out. Among NIO’s advantages, one may name government support as one of the biggest. While the trade war between the US and China is here to stay, the demand is high, and company may cater to Chinese customers first. When it starts conquering the US market, though, the conflict may have already come to an end. The company also admits that the customs duties may indirectly influence the car prices.

The issues NIO might face are already known, and the most obvious one is that of meeting the demand. Over the first 6 months of 2018, NIO had a loss of $502M, while the profit earned afterwards is currently just $7M.

Another risk is in the news that Tesla has come to an agreement with Shanghai authorities to build a car factory in the city, which means high competition for NIO. Still, NIO is likely to win thanks to the price, as the parts for Tesla are produced in the US only, and they are subject to customs duties.

NIO management also announced they had had no mass electric car production experience before, and this may have negative influence on the company growth – an issue already overcome by Tesla. Finally, for ES8, there are around 1,700 used coming from 160 vendors; with so many suppliers, delays in shipments may become quite a common thing.

Many things depend on how NIO is going to rise its production volume and how true the declarations of the management are. Previously, we’ve seen how Elon Musk’s words were sometimes very different from what happened in fact.

One of the key topics here is financing, as the development will require a lot of money. Even Tesla has failed to book net profits so far, its losses and debts still growing.

NIO shares are likely to rise in the short term, as investors will be playing on the fact the company is quite promising at first sight. Other conclusions may be only made after there are at least some financial data at hand.

Technically, there are two support levels for NIO: one at $7 and another at $9.

Disclaimer

Any predictions contained herein are based on the authors’ particular opinion. This analysis shall not be treated as trading advice. RoboForex shall not be held liable for the results of the trades arising from relying upon trading recommendations and reviews contained herein.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.4 stars on average, based on 7 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Continue Reading

Analysis

TEVA: The Time Has Come

Published

on

By Dmitriy Gurkovskiy, Chief Analyst at RoboMarkets

The bull market has made it harder to earn good profits on the share prices of industry leaders. Prices are already high, and the correction may begin at any moment. Day by day, the rumors about crisis spread , and such a crisis is usually expected in the Fall, which is confirmed with the latest 20-year history. Case in point: the dotcom crisis started in early September 2000, with the market reaching its bottom only two years later.

Another fall started in mid Sep 2007, and turned into the global crisis in Aug 2008. Still, the market reached its lowest low and started recovering sooner, in 2009. At the same time, some players are still living the past and waiting for the market to collapse everyday, without noticing the considerable gains that have been made over the years.

There were 7 years between the dotcom and the financial crises. The next major decline occurred in August 2015 but it was short lived and did not result in a major crisis. In 3 years more, Trump became the US president and started resolving the negative trade balance issue by imposing customs duties on China. This, together with tax reforms, supported the markets a lot, and they went on growing. However, the situation is rather tense now, and the fall coming alone may lead to the investors being rather worried. The companies hit their earnings historical highs every quarter, and this may make the management feel dizzy.

Still, there are companies that, unlike most of their counterparts, did not grow following the Trump election. One of them is Teva Pharmaceutical Industries Limited (NYSE: TEVA). When the market started growing after the US elections, TEVA started going down heavily, eventually losing over 80% during 2 years. The company started having problems in 2016 when they bought Allergan (NYSE: AGN) at $40.5B. Before that, TEVA capital had been growing steadily since 2006, while the debts had been at the minimum.

Once TEVA acquired Allergan, the debt went sharply higher, which provoked a selloff immediately. At the same time, the earnings also started falling.

Even the quarterly earnings in 2016 were not enough for investors, as the stock price first did not move much, and then hit the support at $50.00 in the middle of the year and went further down.

The outlook is disappointing, and one would never even think about trading this stock, but still there are some things one should consider well.

Many years ago, many people lived in the countryside or at least used to spend some time there, and few heard of such a thing as an allergy. Then, however, people start migrating to cities, which are very polluted. This, perhaps, led to allergies being quite widespread nowadays. Allergies can be quite dangerous, as in many cases it may provoke an allergic shock, with the patient literally hanging between life and death. In this case, the only thing they need is a medicine that will help them survive before the ambulance arrives.

This is exactly what Teva Pharmaceutical Industries Limited created EpiPen, a medicine that removes allergic shock caused by insect bites, food, other medicines, or physical activity. An injection of EpiPen is enough to stimulate the cardiovascular system and the respiration organs, which prevents the consequences of an allergic shock.

According to some sources, in the US, there are around 43M people who may suffer from allergic shock any minute and should have such a medicine at hand. Ideally, such a person has got to have 2 doses of EpiPen, as sometimes one may be not enough. These two doses cost around $375, while the competition are trying to create the same medicine using adrenaline that should make it much cheaper. Still, they are having problems with medical tests, which means EpiPen has no competition right now. Another point is that it should be used within 12 months; otherwise, you will have to buy another dose. This brings stable profits, the ethical aspect is taken away.

Teva Pharmaceutical Industries Limited is a multinational company with 66 plants in 60 countries. This is one of the biggest pharma companies out there, and it’s no wonder that Warren Buffett has paid attention to it. In Q2, Berkshire Hathaway increased its stake of TEVA shares to 4.3%, or 2,7M shares, and is now one of the top three shareholders.

Meanwhile, in November 2017, a new CEO came to TEVA. Kare Schultz reduced costs drastically, and, as a result, the debt stopped growing first, and then was reduced by over $10B.

Technically, the downtrend is finishing, and an uptrend may start in the midterm, with the support being located at $20.00.

Disclaimer

Any predictions contained herein are based on the authors’ particular opinion. This analysis shall not be treated as trading advice. RoboForex shall not be held liable for the results of the trades arising from relying upon trading recommendations and reviews contained herein.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.4 stars on average, based on 7 rated postsHaving majored in both Social Psychology and Economics, I went on to continue my education in post graduate. Later I worked as a team lead of a tech and fundamental analysis lab in the Applied System Analysis Research Institute. This helped me to acquire all necessary skills and experience to become a successful trader and analyst, as well as a portfolio manager in an investment company. I'm a pro in the financial field and the author of articles for various international media. I also hold the position of Chief Analyst at RoboMarkets.




Feedback or Requests?

Continue Reading

Recent Comments

Recent Posts

A part of CCN

Hacked.com is Neutral and Unbiased

Hacked.com and its team members have pledged to reject any form of advertisement or sponsorships from 3rd parties. We will always be neutral and we strive towards a fully unbiased view on all topics. Whenever an author has a conflicting interest, that should be clearly stated in the post itself with a disclaimer. If you suspect that one of our team members are biased, please notify me immediately at jonas.borchgrevink(at)hacked.com.

Trending